Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease. (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Munoz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, Giraldo P, Mehta A, Park G, Phillips M, Elstein D, Altarescu G, Szleifer M, Hashmueli S, Aviezer D: Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011 Nov 24;118(22):5767-73. doi: 10.1182/blood-2011-07-366955. Epub 2011 Sep 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21900191 # Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld D, Mizrachi S, Liberman Y, Freeman A, Zimran A, Galun E: A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation. PLoS One. 2009;4(3):e4792. doi: 10.1371/journal.pone.0004792. Epub 2009 Mar 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19277123 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| - The half life is between 18.9 to 28.7 min. (en)
|
http://linked.open...ugbank/indication
| - For the treatment of adult Type 1 Gaucher disease. (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Taliglucerase alfa is different from human glucocerebrosidase by two amino acids at the N terminal and up to 7 amino acids at the C terminal. This recombinant enzyme allows the hydrolysis reaction of glucocerebroside to glucose and ceramide that naturally occurs in healthy individuals. (en)
|
http://linked.open...outeOfElimination
| - Route of elimination was not determined. (en)
|
http://linked.open.../drugbank/synonym
| |
http://linked.open...drugbank/toxicity
| - The most common toxic reaction seen was infusion reactions such as urticaria, arthralgia, headache, and chest pain due to IV administration. (en)
|
http://linked.open...umeOfDistribution
| - The steady state volume of distribution is between 7.30 to 11.7 L. (en)
|
http://linked.open...k/foodInteraction
| - No food effects found. (en)
|
http://linked.open...nk/proteinBinding
| - Plasma protein binding was not quantified. (en)
|
http://linked.open...ynthesisReference
| - Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D: Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J. 2007 Sep;5(5):579-90. Epub 2007 May 24. (en)
|
foaf:page
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...ugbank/absorption
| - Taliglucerase alfa is administered IV so absorption is 100%. (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...rugbank/clearance
| - The systemic clearance was approximately 30 L/hr and 20 L/hr for 30 and 60 units/kg, respectively. (en)
|